Screener
Immunovant, Inc. IMVT Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | March 31, 2026 | March 31, 2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Series A preferred stock, par value $0.0001 per share, 10,000 shares authorized, issued and outstanding at March 31, 2026 and March 31, 2025 | — | — |
| Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2026 and March 31, 2025 | — | — |
| Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 203,940,353 shares issued and outstanding at March 31, 2026 and 500,000,000 shares authorized, 170,111,593 shares issued and outstanding at March 31, 2025 | 20 | 16 |
| Additional paid-in capital | 2,596,971 | 1,945,495 |
| Accumulated other comprehensive income | 730 | 1,459 |
| Accumulated deficit | (1,745,129) | (1,239,523) |
| Total stockholders’ equity | 852,592 | 707,447 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s common stock?
- Immunovant, Inc. (IMVT) reported common stock of $20K in Q1 2026.
- How has Immunovant, Inc.'s common stock changed year-over-year?
- Immunovant, Inc.'s common stock increased by 25.0% year-over-year, from $16K to $20K.
- What is the long-term trend for Immunovant, Inc.'s common stock?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s common stock has grown at a 14.9% compound annual growth rate (CAGR), from $10K to $20K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Immunovant, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude